We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Active Compound in Popular Heartburn Drug Pepcid Being Tested for COVID-19 Treatment

By HospiMedica International staff writers
Posted on 29 Apr 2020
A trial for famotidine, the active compound in the over-the-counter heartburn medication Pepcid, is underway at the Feinstein Institutes for Medical Research (Manhasset, NY, USA) to study if the drug can make a difference in the treatment of COVID-19 patients.

The researchers decided to conduct a drug trial for famotidine after encouraging reports from China. More...
A review of 6,212 COVID-19 patient records revealed that a large number of survivors had been experiencing chronic heartburn and were taking famotidine instead of omeprazole (Prilosec) which is more expensive and preferred in the US and among the wealthier population in China. Hospitalized COVID-19 patients who were taking famotidine seemed to have a lower death rate of 14% as against 27% for patients who were not taking the drug.

Additionally, molecular modeling results also suggested that famotidine, which appears to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could deliver results. Famotidine is believed to bind to an enzyme critical to COVID-19. Similar to how protease inhibitors, which are used to treat HIV, stop the virus, famotidine’s structure can stop the coronavirus from replicating, at least theoretically.

The Feinstein Institutes for Medical Research received clearance from the US Food and Drug Administration to conduct a trial using the intravenous version of famotidine. In addition to Gilead Sciences’ remdesivir and the anti-malarial drug hydroxychloroquine, the researchers are now also assessing famotidine in a small clinical trial which has enrolled 187 critical COVID-19 patients so far, including several on ventilators, and aims for a total of 1174 people. In the trial the patients are being intravenously administered nine times the amount of famotidine that a person would normally take to treat heartburn,

The researchers have been keeping the clinical trial of famotidine under wraps to ensure sufficient supply for their study, as well as avoid a rush to medication stores for the drug which would deny people with heartburn or stomach ulcers access to the drug.

Related Links:
Feinstein Institutes for Medical Research


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Electrically Operated Patient Lifter
SVL 205
New
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Researchers have unlocked the heart’s hidden geometry that could revolutionize ECG interpretation (Photo courtesy of KCL)

Discovery of Heart’s Hidden Geometry to Revolutionize ECG Interpretation

Electrocardiograms (ECGs) are one of the most widely used tools in diagnosing heart conditions, but their accuracy can be affected by natural variations in individual heart anatomy. Traditional ECG interpretation... Read more

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.